Tissue Microarrays from Frozen Tissues-OCT Technique

  • Marlena Schoenberg FejzoEmail author
  • Dennis J. Slamon
Part of the Methods in Molecular Biology book series (MIMB, volume 664)


Tissue microarray technology is a new method used to analyze 100s to 1,000s of tumor samples on a single slide allowing high throughput analysis of genes and proteins on a large cohort. The original methodology involves coring tissues from paraffin-embedded tissue donor blocks and placing them into a single paraffin block. One difficulty with paraffin-embedded tissue relates to antigenic changes in proteins and mRNA degradation induced by the fixation and embedding process. We modified this technology by using frozen tissues embedded in OCT compound as donor samples and arraying the specimens into a recipient OCT block. Tumor tissue is not fixed before embedding, and sections from the array are evaluated without fixation or postfixed according to the appropriate methodology used to analyze a specific gene at the DNA, RNA, and/or protein levels. While paraffin tissue arrays can be problematic for immunohistochemistry and for RNA in situ hybridization analyses, this method allows optimal evaluation by each technique and uniform fixation across the array panel. Frozen tissue microarrays work well for DNA, RNA, and protein analyses, and may have significant advantages over the original technology for the assessment of some genes and proteins by improving both qualitative and quantitative results.

Key words

Frozen Tissue microarray technology Immunohistochemistry 


  1. 1.
    Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998): Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4:844–847.PubMedCrossRefGoogle Scholar
  2. 2.
    Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G (1999): Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res, 5:1966–1975.PubMedGoogle Scholar
  3. 3.
    Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G (1999): High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol, 154:981–986.PubMedCrossRefGoogle Scholar
  4. 4.
    Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999): Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res, 59:803–806.PubMedGoogle Scholar
  5. 5.
    Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP (1999): Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst, 91:1758–1764.PubMedCrossRefGoogle Scholar
  6. 6.
    Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G (1999): Identification of prognostic parameters for renal cell carcinoma by cDNA arrays and cell chips. Verh Dtsch Ges Pathol, 83:225–232.PubMedGoogle Scholar
  7. 7.
    Barlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, Kallioniemi A (2000): Detecting activation of ribosomal protein 86 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst, 92:1252–1259.PubMedCrossRefGoogle Scholar
  8. 8.
    Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi OP, Kallioniemi A (2000): Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res, 60:5340–5344.PubMedGoogle Scholar
  9. 9.
    Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G (2000): High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol, 157:787–794.PubMedCrossRefGoogle Scholar
  10. 10.
    Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP (2000): Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res, 60:6111–6115.PubMedGoogle Scholar
  11. 11.
    Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K (1999): Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res, 27:4436–4443.PubMedCrossRefGoogle Scholar
  12. 12.
    Werner M, Chott A, Fabiano A, Battifora H (2000): Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol, 24:1016–1019.PubMedCrossRefGoogle Scholar
  13. 13.
    Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H (2001): Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol, 158:419–429.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldsworthy SM, Stockton PS, Trempus CS, Foley JF, Maronpot RR (1999): Effects of fixation on RNA extraction and amplification from laser capture microdissected tissue. Mol Carcinog, 25:86–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Battifora H, Kopinski M (1986): The influence of protease digestion and duration of fixation on the immunostaining of keratins: a comparison of formalin and ethanol fixation. J Histochem Cytochem, 34:1095–1100.PubMedCrossRefGoogle Scholar
  16. 16.
    Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J (1994): Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol, 173:65–75.PubMedCrossRefGoogle Scholar
  17. 17.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989): Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244:707–712.PubMedCrossRefGoogle Scholar
  18. 18.
    Battifora H (1991): Effect of fixatives and fixation times on tissues. Am J Clin Pathol, 96:144–145.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of Medicine, School of MedicineUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations